https://www.zerohedge.com/geopolitical/putin-says-all-ukraine-ours-theory-raises-takeover-sumy

Sana Bio to Present Novel Immunosuppression-Free Diabetes Cell Therapy Data at ADA

Sana Biotechnology (NASDAQ: SANA) will present updated six-month clinical results for UP421, their hypoimmune-modified primary islet cell therapy for type 1 diabetes, at the 85th Annual American Diabetes Association Scientific Sessions. The presentation, scheduled for June 23, 2025, in Chicago, will highlight data from a first-in-human study where UP421, an allogeneic primary islet cell therapy using Sana's hypoimmune (HIP) technology, was transplanted into a patient without requiring immunosuppression. The presentation will be part of a joint symposium between the American Diabetes Association (ADA) and International Pancreas & Islet Transplant Association (IPITA) focused on immune protection for cell replacement therapy.

https://www.stocktitan.net/news/SANA/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-dgfi1hleqvyt.html

MannKind to Highlight Recent Data on Inhaled Insulin (Afrezza®) at ADA

 MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase inhaled insulin at the American Diabetes Association’s (ADA) 85th Scientific Sessions from June 20-23 in Chicago.

Dr. Michael J. Haller, Professor and Chief of Pediatric Endocrinology at the University of Florida, will present the results from the randomized period of the INHALE-1 clinical trial during a “Future Ready” symposium. Dr. Haller is the Chair for MannKind’s Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age).

The presentation/posters planned at ADA’s 85th Scientific Sessions regarding the most recent advances in inhaled insulin treatment include:

Symposium – Future Ready – Breakthrough in Pediatric Type 1 Diabetes Care
Sunday, June 22 – 1:30 to 3:00 p.m. (Central) in Room W 181(A-C)
Dr. Michael J. Haller will present: From Discovery to Treatment – Latest Updates on Inhaled Insulin Treatment

Patient Reported Outcomes with Use of Inhaled Technosphere Insulin (T1) (Board 827)
Saturday, June 21, 2025 – 12:30 to 1:30 p.m. (Central)
Presenter: Dr. Peter Calhoun

Efficacy and Safety of Prandial Technosphere Inhaled Insulin (Afrezza) Compared with Placebo in Adult Individuals with T2DM – Results from a Phase III Clinical Trial from India (Board No. 833)
Saturday, June 21, 2025 – 12:30 to 1:30 p.m. (Central)
Presenter: Dr. K M Prasanna Kumar

https://www.globenewswire.com/news-release/2025/06/09/3096180/0/en/MannKind-to-Highlight-Data-from-Recent-Pediatric-and-Adult-Studies-of-Inhaled-Insulin-Afrezza-at-American-Diabetes-Association-s-85th-Scientific-Sessions-in-Chicago-June-20-23.html

Fractyl New Preclinical Data from Rejuva® Smart GLP-1 Pancreatic Gene Therapy Platform at ADA

Fractyl Health (NASDAQ: GUTS), a metabolic therapeutics company, will present new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform at the American Diabetes Association's 85th Scientific Sessions. The presentation, scheduled for June 22, 2025, will showcase results from a study titled 'Single-Dose GLP-1–Based Pancreatic Gene Therapy Prevents Obesity and Diabetes in High-Fat–Fed Mice.' The poster session will take place at the ADA conference in Chicago from June 20-23, 2025, with the specific presentation scheduled for 12:30-1:30 PM in Hall F1. The data will be made available on Fractyl's website after the conference presentation.

https://www.stocktitan.net/news/GUTS/fractyl-health-to-present-new-preclinical-data-from-its-rejuva-smart-6vsoyam47pf2.html

Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA

 

New State of Type 2 Report in the United States reports that a majority of healthcare professionals (HCPs) surveyed believe continuous glucose monitoring will have the potential to be more impactful on the future of Type 2 diabetes care than advancements in diabetes medications.1
Dexcom Warrior Lance Bass will share first-hand experience saying “Bye” to fingersticks* during panel at ADA.

DexCom, Inc., the global leader in glucose biosensing, today released its "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" ahead of the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. The findings provide valuable insights into the perceptions around diabetes technology from more than 400 healthcare professionals and people with Type 2 diabetes across the United States.

https://www.stocktitan.net/news/DXCM/dexcom-unveils-new-report-on-type-2-diabetes-management-in-the-u-s-0zfddzvcu816.html

New Data Shows Lexicon's Diabetes Drug Effective Across All Kidney Function Levels - ADA

Lexicon Pharmaceuticals (LXRX) will present clinical data at the 85th ADA Scientific Sessions on June 20-23, 2025, in Chicago. The presentation focuses on sotagliflozin's ability to reduce hypoglycemic events in type 1 diabetes patients across different kidney function levels, categorized by eGFR ranges. Dr. M. Belinda Hardin will deliver an oral presentation on June 22 discussing these findings. Additionally, Lexicon will present topline results from their PROGRESS Phase 2b study of pilavapadin (LX9211), evaluating its effectiveness in treating diabetic peripheral neuropathic pain. The presentations align with ADA's 2025 Standards of Care emphasis on preventing hypoglycemia in type 1 diabetes management.

https://www.stocktitan.net/news/LXRX/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-6y3brdoy049n.html

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at ADA

 – Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit –

– All 12 patients with at least one year of follow-up who received a full dose of zimislecel as a single infusion achieved ADA-recommended target HbA1c levels <7% and >70% time-in-range (70-180 mg/dL), and 10/12 patients were insulin free –

– Data presented at ADA simultaneously published in the New England Journal of Medicine –

– Vertex to host investor webcast tonight, June 20, 2025, at 7:15 p.m. CT / 8:15 p.m. ET –

Vertex will host an investor event on Friday, June 20, 2025, at 7:15 p.m. CT/8:15 p.m. ET, in Chicago, to discuss the positive zimislecel data in type 1 diabetes. A live webcast of the presentation and Q&A portions can be accessed through the Investor Relations section of Vertex's website at https://investors.vrtx.com/. An archived webcast will be available on the company's website.

https://finance.yahoo.com/news/vertex-presents-positive-data-zimislecel-231500649.html